 20 million Americans are actively treated with statins at an annual cost of 16 billion dollars. Statins are effective therapeutic agents for reducing LDL cholesterol and have documented effectiveness. However, a significant subset of patients 5-18, cannot tolerate lipid lowering statin therapy due to intolerable muscle-related symptoms characterized by muscle pain andor weakness. These symptoms affect quality of life and lead to poor adherence. 